Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion
| Autor: | Zafer Baslar, Burhan Ferhanoglu, Teoman Soysal, Fevzi Firat Yalniz, Yildiz Aydin, Enes Ali Kurt, Deniz Eyice, Ayse Salihoglu, Muhlis Cem Ar, Seniz Ongoren Aydin, Ahmet Emre Eskazan, Ugur Ozbek, Nukhet Tuzuner, Tugrul Elverdi |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Adolescent Lymphocytosis Pleural effusion Dasatinib Leukemia Myelogenous Chronic BCR-ABL Positive hemic and lymphatic diseases Internal medicine medicine Humans Protein Kinase Inhibitors Survival rate Aged Aged 80 and over business.industry Imatinib Hematology Middle Aged medicine.disease Comorbidity Surgery Pleural Effusion Survival Rate Thiazoles Pyrimidines Treatment Outcome Oncology Effusion Nilotinib Female Neoplasm Grading medicine.symptom business medicine.drug |
| Zdroj: | Leukemia Research. 38:781-787 |
| ISSN: | 0145-2126 |
| DOI: | 10.1016/j.leukres.2014.04.004 |
| Popis: | Dasatinib is a potent second generation TKI, and it is widely used in patients with CML, both in the up-front setting and failure after imatinib. Lymphocytosis in cases receiving dasatinib therapy has been shown to be associated with pleural effusion (PE) and better outcome. Although patients who gather lymphocytosis during dasatinib have superior responses, there is only little data about the correlation between PE, response rates, and survival. In order to answer this question, the aim of our study was to determine the frequency of PE and lymphocytosis among our CML patients receiving second-line dasatinib, and to compare the responses and outcomes between patients with or without PE. There were 18 patients (44%) who developed PE, in a total of 41 patients, with a median time of 15 months. Lymphocytosis was observed in nine patients (9/41, 22%) with a median duration of 6.5 months of dasatinib treatment. There were fourteen patients with at least one comorbidity that may play a role in the generation of PE. The cumulative MMR and CCyR rates were greater in PE+ patients (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect